Metabolic endotoxemia is dictated by the type of lipopolysaccharide

• Published in: Cell reports (Cambridge) Vol. 36; no. 11; p. 109691
• Main Authors: Anhê, Fernando F., Barra, Nicole G., Cavallari, Joseph F., Henriksbo, Brandyn D., Schertzer, Jonathan D.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 14.09.2021; Elsevier
• Subjects: Adipose Tissue - drug effects; Adipose Tissue - metabolism; Adipose Tissue - pathology; Animals; Blood Glucose - analysis; Body Weight - drug effects; diabetes; Endotoxemia - etiology; Endotoxemia - metabolism; Escherichia coli - metabolism; Glucagon-Like Peptide 1 - blood; Glucose - metabolism; immunometabolism; inflammation; Insulin - blood; Intestines - drug effects; Intestines - metabolism; Lipopolysaccharides - pharmacology; Male; Mice; Mice, Inbred C57BL; Mice, Obese; microbiome; microbiota; obesity; Obesity - metabolism; Obesity - pathology; Peptidoglycan - pharmacology; Rhodobacter sphaeroides - metabolism; Toll-Like Receptor 4 - agonists; Toll-Like Receptor 4 - metabolism; microbiota; immunometabolism; inflammation; diabetes; microbiome; obesity

Lipopolysaccharides (LPSs) can promote metabolic endotoxemia, which is considered inflammatory and metabolically detrimental based on Toll-like receptor (TLR)4 agonists, such as Escherichia coli-derived LPS. LPSs from certain bacteria antagonize TLR4 yet contribute to endotoxemia measured by endotox...